Mediterranean diet effects on vascular health and serum levels of ...
WEBAug 15, 2024 · 1. The effect of the Mediterranean Diet on cardiovascular health can be partially explained by improved vascular health, lowered total cholesterol and LDL, lowered ceramides, and reduced serum inflammatory adipokines. Evidence Rating Level: 1 (Excellent) Study Rundown: The Mediterranean Diet has been previously shown to improve cardiovascular outcomes in patients. This is proposed to be
Early occupational therapy improves post-stroke outcomes
WEBAug 27, 2024 · 1. Early occupational therapy in stroke patients significantly improves recovery of functional independence, quality of life, cognition skills, and level of depression 3 months post-discharge Evidence Rating Level: 1 (Excellent) Strokes incur significant changes in patients’ lives causing health, social, and economic problems that can cause disability. Additionally, there is an increasing ...
Infusion with a monoclonal antibody decreases migraine frequency
WEBSep 30, 2024 · 1. In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal antibody against pituitary adenylate cyclase-activating polypeptide (PACAP), Lu AG09222, was associated with a reduction in migraines frequency. 2. The Lu AG09222 group experienced a higher incidence of adverse events compared to the placebo group, though no
Landmark Trials & Summaries: The Classics in Medicine - 2 Minute …
WEB3800. 1.It was found that adverse events occurred in 3.7% of hospitalizations 2.Approximately 27.6% of adverse events occurring in hospital were attributed to negligence. The OHTS trial: Topical ocular hypotensive medication reduces risk of open-angle glaucoma.
Semaglutide reduces cardiovascular events in patients with ...
WEBSep 5, 2024 · 1. Patients assigned to semaglutide reported reduced major adverse cardiovascular events, regardless of heart failure subtype. 2. Benefits were consistent across baseline characteristics such as age, BMI, and diuretic use. Evidence Rating Level: 1 (Excellent) Study Rundown: Semaglutide is known to reduce the risk of major adverse cardiovascular events (MACE) in overweight and obese patients;
Biguanides and dipeptidyl peptidase-4 inhibitors use have similar ...
WEBAug 16, 2024 · 1. Biguanides and dipeptidyl peptidase-4 (DPP-4) inhibitors show no differences in major cardiac or cerebrovascular events, diabetic complications, or death in the Japanese population. Evidence Rating Level: 2 (Good) The initial pharmacologic intervention for type 2 diabetes mellitus (T2DM) includes biguanides and dipeptidyl peptidase-4 (DPP-4) inhibitors.
Eli Lilly: Kisunla was shown to reduce symptoms and slow disease ...
WEBAug 30, 2024 · Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of treatment and a 39% reduced risk of disease progression to the next clinical stage. Amyloid-related imaging abnormalities, which include swelling or bleeding in the brain, occurred …
Early intensive glycemic control reduces long-term risk of death …
WEBAug 15, 2024 · In-depth [randomized controlled trial]: Between 1977 and 1991, 5102 patients were screened for eligibility of which 1489 were ultimately included in the final analysis for the 14-year post-trial monitoring study. Included were patients with newly diagnosed type 2 diabetes (T2DM) who were assigned to either intensive glycaemic control or conventional glycaemic control.
Semaglutide reduces heart failure events in patients with …
WEBSep 24, 2024 · 1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant difference was observed between groups for cardiovascular death alone. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure, affecting patients with obesity,
Home | 2 Minute Medicine
WEBNeuroprosthesis enables conversational communication in amyotrophic lateral sclerosis. by Nhat Hung (Benjamin) Lam and 1 others. October 4, 2024. 1. A participant with amyotrophic lateral sclerosis (ALS) and severe dysarthria underwent surgical implantation of microelectrode arrays set up to decode cortical activity as he attempted to speak. 2.